```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:28:34 ON 25 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 MAY 2003  HIGHEST RN 519387-75-8
DICTIONARY FILE UPDATES:  23 MAY 2003  HIGHEST RN 519387-75-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l59
L1       438185 SEA FILE=REGISTRY ABB=ON  PLU=ON  (NCSC2 OR NOC3)/ES AND NR>=3

L5              STR
```




```
VAR G1=CH2/O/S/27/23/19/12/16
REP G2=(0-1) CH2
REP G3=(1-2) CH2
NODE ATTRIBUTES:
NSPEC   IS R      AT  12
NSPEC   IS R      AT  16
CONNECT IS M1  RC AT   9
CONNECT IS M1  RC AT  11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE
L54             STR
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov




```
VAR G1=C/O/S
REP G2=(0-1) C
REP G3=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L56          532 SEA FILE=REGISTRY SUB=L1 SSS FUL L54
L59           22 SEA FILE=REGISTRY SUB=L56 CSS FUL L5

100.0% PROCESSED    532 ITERATIONS                          22 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 09:53:07 ON 25 MAY 2003)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 09:53:21 ON 25 MAY 2003
L1         438185 S (NCSC2 OR NOC3)/ES AND NR>=3
L2                STR
L3                0 S L2 CSS SAM SUB=L1
L4                1 S L2 SAM SUB=L1
L5                  STR L2
L6                0 S L5 CSS SAM SUB=L1
L7                2 S L5 SAM SUB=L1

     FILE 'HCAPLUS' ENTERED AT 09:58:00 ON 25 MAY 2003
               E US20020133023/PN
L8                1 S E3
                  SEL RN

     FILE 'REGISTRY' ENTERED AT 09:58:56 ON 25 MAY 2003
L9              393 S E1-E393
L10              17 S L9 AND L1
L11              23 S L9 AND (NCSC2 OR NOC3)/ES
L12              23 S L10,L11
L13               6 S L11 NOT L10
L14             370 S L9 NOT L10-L13
L15             202 S L14 AND NR>=3
L16              80 S L15 NOT C2N2O/EA
L17              12 S L16 NOT C3N2/RF

     FILE 'HCAPLUS' ENTERED AT 10:06:35 ON 25 MAY 2003
               E NAGARAJAN S/AU
```

```
L18          124 S E3,E5,E8
L19           49 S E18-E22
                 E SRINIVASAN/AU
L20           29 S E3
                 E SRINIVASAN N/AU
L21          224 S E3,E7
                 E SRINIVASAN R/AU
L22          990 S E3
                 E KHANNA I/AU
L23           57 S E4,E7-E9
                 E TOLLEFSON M/AU
L24           17 S E6,E7
                 E MOHLER S/AU
L25            3 S E3,E4
                 E MOEHLER S/AU
L26           24 S E3
                 E CHEN B/AU
L27          597 S E3-E30
                 E CHEN BARB/AU
L28           31 S E4-E6
                 E RUSSELL M/AU
L29          352 S E3-E29,E54-E66
                 E DEVADAS B/AU
L30           67 S E3-E6
                 E PENNING T/AU
L31           59 S E4,E6-E8
                 E SCHRETZMAN L/AU
L32           13 S E4-E6
                 E SPANGLER D/AU
L33           47 S E3,E6-E9
                 E BOYS M/AU
L34           13 S E4,E5
                 E CHANDRAKUMAR N/AU
L35           89 S E3,E5-E7
                 E LU H/AU
L36          276 S E3,E8
                 E LU HUNG/AU
                 E LU HWANG/AU
L37           20 S E4
                 E L18-L37 AND PHARMAC?/PA,CS
L38           24 S L18-L37 AND PHARMACIA?/PA,CS
L39           23 S L18-L37 AND INTEGRIN
L40          168 S L18-L37 AND HET?/SC,SX
L41           51 S L18-L37 AND (?THIAZOL? OR ?ISOXAZOL?)
L42           11 S L39 AND L40,L41
L43           11 S L38 AND L39,L41,L42
L44           16 S L42,L43
L45           13 S L40 AND L44
L46            5 S L41 AND L44
L47           13 S L45,L46
L48            3 S L44 NOT L47
L49           12 S L47 NOT L8

     FILE 'REGISTRY' ENTERED AT 10:17:09 ON 25 MAY 2003

     FILE 'HCAPLUS' ENTERED AT 10:17:10 ON 25 MAY 2003
                 SET SMARTSELECT ON
L50           SEL L49 1- RN :    3554 TERMS
                 SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 10:17:11 ON 25 MAY 2003
L51          3554 S L50
L52            19 S L1 AND L51
```

```
L53          17 S L51 AND (NCSC2 OR NOC3)/ES NOT L52
L54             STR L5
L55          29 S L54 SAM SUB=L1
L56         532 S L54 FUL SUB=L1
                SAV TEMP L56 DENTZ881/A
L57          20 S L9,L51 AND L56
L58           0 S L5 CSS SAM SUB=L56
L59          22 S L5 CSS FUL SUB=L56
L60           2 S L59 NOT L57
                SAV TEMP L59 DENTZ881A/A
L61          22 S L57,L59,L60
L62           5 S L61 NOT L10
L63          17 S L61 NOT L62

     FILE 'HCAOLD' ENTERED AT 10:25:52 ON 25 MAY 2003
L64           0 S L63
L65           0 S L62

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:25:59 ON 25 MAY 2003
L66           0 S L63
L67           5 S L62
L68           4 S L67 NOT (G06F OR G06T)/IC,ICM,ICS

     FILE 'HCAPLUS' ENTERED AT 10:27:36 ON 25 MAY 2003
L69           1 S L63
L70           2 S L62
L71           3 S L69,L70
L72           2 S L71 AND L8,L18-L49
L73           1 S L71 NOT L72

     FILE 'REGISTRY' ENTERED AT 10:28:34 ON 25 MAY 2003

=> d ide can tot l63

L63  ANSWER 1 OF 17  REGISTRY  COPYRIGHT 2003 ACS
RN   381674-66-4  REGISTRY
CN   5-Isoxazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-3-[2-(1,5,6,7-
     tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   3-Benzo[1,3]dioxol-5-yl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-
     yl)ethoxy]isoxazol-5-yl]butyric acid
FS   3D CONCORD
MF   C24 H25 N3 O6
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              1 REFERENCES IN FILE CA (1957 TO DATE)
```

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-62-0** REGISTRY
CN 3-Pyridinepropanoic acid, .beta.-[[3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Pyridin-3-yl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]isoxazol-5-yl]butyric acid
FS 3D CONCORD
MF C22 H24 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-58-4** REGISTRY
CN 5-Isoxazolebutanoic acid, .beta.-(3-fluorophenyl)-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(3-Fluorophenyl)-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]isoxazol-5-yl]butyric acid
FS 3D CONCORD
MF C23 H24 F N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-55-1** REGISTRY
CN 5-Isoxazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(2,3-Dihydrobenzofuran-6-yl)-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]isoxazol-5-yl]butyric acid
FS 3D CONCORD
MF C25 H27 N3 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-54-0** REGISTRY
CN 5-Isoxazolebutanoic acid, .beta.-phenyl-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Phenyl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-

yl)ethoxy]isoxazol-5-yl]butyric acid
FS 3D CONCORD
MF C23 H25 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-26-6** REGISTRY
CN 2-Thiazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Benzo[1,3]dioxol-5-yl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]butyric acid
FS 3D CONCORD
MF C25 H27 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-23-3** REGISTRY
CN 3-Pyridinepropanoic acid, .beta.-[[4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Pyridin-3-yl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]butyric acid
FS 3D CONCORD
MF C23 H26 N4 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-20-0** REGISTRY
CN 2-Thiazolebutanoic acid, .beta.-(3-fluorophenyl)-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(3-Fluorophenyl)-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]butyric acid
FS 3D CONCORD
MF C24 H26 F N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-18-6** REGISTRY
CN 2-Thiazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(2,3-Dihydrobenzofuran-6-yl)-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]butyric acid
FS 3D CONCORD
MF C26 H29 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-17-5** REGISTRY
CN 2-Thiazolebutanoic acid, .beta.-phenyl-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Phenyl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]butyric acid
FS 3D CONCORD
MF C24 H27 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381674-14-2** REGISTRY
CN Cyclopropaneacetic acid, 2-[4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [2-[4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)propyl]thiazol-2-yl]cyclopropyl]acetic acid
FS 3D CONCORD
MF C19 H23 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-88-7** REGISTRY
CN 3-Isoxazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Benzo[1,3]dioxol-5-yl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]isoxazol-3-yl]butyric acid
FS 3D CONCORD
MF C25 H27 N3 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-85-4** REGISTRY
CN 3-Pyridinepropanoic acid, .beta.-[[5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-3-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Pyridin-3-yl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]isoxazol-3-yl]butyric acid
FS 3D CONCORD
MF C23 H26 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-82-1** REGISTRY
CN 3-Isoxazolebutanoic acid, .beta.-(3-fluorophenyl)-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 3-(3-Fluorophenyl)-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]isoxazol-3-yl]butyric acid
FS 3D CONCORD
MF C24 H26 F N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-79-6** REGISTRY
CN 3-Isoxazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(2,3-Dihydrobenzofuran-6-yl)-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]isoxazol-3-yl]butyric acid
FS 3D CONCORD
MF C26 H29 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-76-3** REGISTRY
CN 3-Isoxazolebutanoic acid, .beta.-phenyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Phenyl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]isoxazol-3-yl]butyric acid
FS 3D CONCORD
MF C24 H27 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

L63 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **381673-72-9** REGISTRY
CN Cyclopropaneacetic acid, 2-[5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [2-[5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)propyl]isoxazol-3-yl]cyclopropyl]acetic acid
FS 3D CONCORD
MF C19 H23 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53749

=> d ide can tot l62

L62 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN **381226-25-1** REGISTRY
CN Cyclopropaneacetic acid, 2-[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]-1-(5-thiazolyl)- (9CI) (CA INDEX NAME)
MF C24 H25 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

FYI only



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53681

L62 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN **381226-22-8** REGISTRY
CN Cyclopropaneacetic acid, 1-(5-isoxazolyl)-2-[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)
MF C24 H25 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53681

L62 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN **381226-21-7** REGISTRY
CN Cyclopropaneacetic acid, 1-(3-isoxazolyl)-2-[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)
MF C24 H25 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:53681

L62 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 243642-64-0 REGISTRY
CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, (.beta.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H25 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 131:214194

L62 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 243642-29-7 REGISTRY
CN 2-Thiazolepropanoic acid, .beta.-[[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]methyl]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 131:214194

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:29:02 ON 25 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l72

L72 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:923795 HCAPLUS
DN 136:53749
TI Preparation of heteroarylalkanoic acids as **integrin** receptor antagonists
IN **Nagarajan, Scrinivasan Raj; Khanna, Ish Kumar; Tollefson, Michael B.; Mohler, Scott B.; Chen, Barbara; Russell, Mark; Devadas, Balekudru; Penning, Thomas D.; Schretzman, Lori A.; Spangler, Dale P.; Boys, Mark Laurence; Chandrakumar, Nizal Samuel; Lu, Hwang-Fun**
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 368 pp.
CODEN: PIXXD2
DT Patent
LA English

IC ICM C07D471-00
CC 28-10 (**Heterocyclic** Compounds (More Than One **Hetero** Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001096334	A2	20011220	WO 2001-US19375	20010615
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002133023	A1	20020919	US 2001-881913	20010615 <--
	EP 1289983	A2	20030312	EP 2001-948424	20010615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-211781P	P	20000615		
	US 2000-211782P	P	20000615		
	WO 2001-US19375	W	20010615		

OS MARPAT 136:53749
GI



II

AB Title compds. A1Z2Z1AXYY5(Y3)(Y4)CH2CORb [I; wherein ring A = (un)substituted 4-8 membered monocyclic or 7-12 membered bicyclic ring contg. 1-4 heteroatoms, selected from O, N, or S; A1 = (un)substituted 5-9 membered monocyclic or 7-14 membered polycyclic heterocycle contg. at least 1 N and optionally 1-4 heteroatoms or groups selected from O, N, S, SO2, or CO; Z1 = CH2, O, CH2O, NH, CO, S, SO, CH(OH), and SO2; Z2 = (un)substituted 1-5 C linker optionally contg. 1 or more heteroatoms selected from O, S, and N; Z1Z2 may contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, acyl, or (un)substituted 5- or 6-membered (hetero)aryl; X = CHRe, NRf, O, S, SO2, or CO; Re = H, (cyclo)alkyl, alkoxy(alkyl), OH, alkynyl, alkenyl, haloalkyl, thioalkyl, or aryl; Rf = H, (halo)alkyl, aryl, or benzyl; Y = (CH2)p, CHRg, NRg, CO, or SO2; Rg = H, (halo)alkyl, alkoxyalkyl, alkynyl, (hetero)aryl, OH, alkoxy, or carboxyalkyl; p = 0-1; XY may contain acyl, alkyl, sulfonyl, amino, (thio)ether, carboxamido, sulfonamido, aminosulfonyl, or olefin; Y3 and Y4 = independently H, (halo)alkyl, halo, (hetero)aryl, hydroxyalkyl, alkynyl, etc.; Rb = X2Rh; X2 = O, S, or NRj; Rh and Rj = independently H, (ar)alkyl, acyl, or alkoxyalkyl; with provisos] and their pharmaceutically acceptable salts were prepd. for selectively antagonizing the .alpha.v.beta.3 and/or the .alpha.v.beta.5 **integrin** without significantly antagonizing the fibrinogen IIb/IIIa **integrin**. For example, 3-(hydroxymethyl)benzonitrile was protected with 3,4-dihydro-2H-pyran (89%) and treated with HONH2.bul.HCl to give the benzenecarboximidamide (98%). Cyclization with 3-methylglutaric anhydride in the presence of MeI (64%) and deprotection (98%) gave the Me

1,2,4-oxadiazolebutanoate (64%). Oxidn. to the aldehyde, followed by reductive addn. of 2-aminopyridine and workup, afforded the oxadiazolebutanoic acid (II). In vitronectin adhesion assays, I antagonized the .alpha.v.beta.3 **integrin** and the .alpha.v.beta.5 **integrin** with IC50 values of 0.1 nM to 100 .mu.M and < 50 .mu.M, resp. I are useful for the treatment of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis (no data).

ST heteroarylalkanoic acid prepn vitronectin **integrin** receptor antagonist; oxadiazolealkanoic acid prepn antitumor agent angiogenesis inhibitor

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IIIa; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Cytotoxic agents
(compns. of heteroarylalkanoic acid **integrin** receptor antagonists with cytotoxic agents)

IT Neoplasm
(humoral hypercalcemia of malignancy, treatment; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Eye, disease
(macula, degeneration, treatment; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Angiogenesis inhibitors
Antiarthritics
Antitumor agents
(prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Artery, disease
(restenosis, treatment; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Eye, disease
(retinopathy, treatment; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Osteoporosis
(therapeutic agents; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT Cell migration
(treatment of smooth muscle; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.IIb; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.3; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.5; prepn. of heteroarylalkanoic acid **integrin**

(1Z)-N'-Hydroxy-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanimidamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

IT **381673-72-9P**, [2-[5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)propyl]**isoxazol**-3-yl]cyclopropyl]acetic acid
381673-76-3P, 3-Phenyl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**isoxazol**-3-yl]butyric acid
381673-79-6P, 3-(2,3-Dihydrobenzofuran-6-yl)-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**isoxazol**-3-yl]butyric acid **381673-82-1P**, 3-(3-Fluorophenyl)-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]**isoxazol**-3-yl]butyric acid **381673-85-4P**, 3-Pyridin-3-yl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**isoxazol**-3-yl]butyric acid
381673-88-7P, 3-Benzo[1,3]dioxol-5-yl-4-[5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**isoxazol**-3-yl]butyric acid
381674-14-2P, [2-[4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]cyclopropyl]acetic acid
381674-17-5P, 3-Phenyl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]butyric acid
381674-18-6P, 3-(2,3-Dihydrobenzofuran-6-yl)-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]butyric acid **381674-20-0P**, 3-(3-Fluorophenyl)-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]butyric acid **381674-23-3P**, 3-Pyridin-3-yl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]butyric acid
381674-26-6P, 3-Benzo[1,3]dioxol-5-yl-4-[4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)propyl]**thiazol**-2-yl]butyric acid
381674-54-0P, 3-Phenyl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]**isoxazol**-5-yl]butyric acid
381674-55-1P, 3-(2,3-Dihydrobenzofuran-6-yl)-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]**isoxazol**-5-yl]butyric acid **381674-58-4P**, 3-(3-Fluorophenyl)-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]**isoxazol**-5-yl]butyric acid **381674-62-0P**, 3-Pyridin-3-yl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]**isoxazol**-5-yl]butyric acid
381674-66-4P, 3-Benzo[1,3]dioxol-5-yl-4-[3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)ethoxy]**isoxazol**-5-yl]butyric acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarylalkanoic acid **integrin** receptor antagonists as antitumor agents, angiogenesis inhibitors, and antiarthritics)

RN 381673-72-9 HCAPLUS
CN Cyclopropaneacetic acid, 2-[5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 381673-76-3 HCAPLUS
CN 3-Isoxazolebutanoic acid, .beta.-phenyl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381673-79-6 HCAPLUS
CN 3-Isoxazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381673-82-1 HCAPLUS
CN 3-Isoxazolebutanoic acid, .beta.-(3-fluorophenyl)-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381673-85-4 HCAPLUS
CN 3-Pyridinepropanoic acid, .beta.-[[5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-3-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 381673-88-7 HCAPLUS
CN 3-Isoxazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-5-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381674-14-2 HCAPLUS
CN Cyclopropaneacetic acid, 2-[4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 381674-17-5 HCAPLUS
CN 2-Thiazolebutanoic acid, .beta.-phenyl-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381674-18-6 HCAPLUS
CN 2-Thiazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381674-20-0 HCAPLUS
CN 2-Thiazolebutanoic acid, .beta.-(3-fluorophenyl)-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381674-23-3 HCAPLUS
CN 3-Pyridinepropanoic acid, .beta.-[[4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 381674-26-6 HCAPLUS
CN 2-Thiazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-4-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



RN 381674-54-0 HCAPLUS
CN 5-Isoxazolebutanoic acid, .beta.-phenyl-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 381674-55-1 HCAPLUS
CN 5-Isoxazolebutanoic acid, .beta.-(2,3-dihydro-6-benzofuranyl)-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 381674-58-4 HCAPLUS
CN 5-Isoxazolebutanoic acid, .beta.-(3-fluorophenyl)-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 381674-62-0 HCAPLUS
CN 3-Pyridinepropanoic acid, .beta.-[[3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 381674-66-4 HCAPLUS
CN 5-Isoxazolebutanoic acid, .beta.-1,3-benzodioxol-5-yl-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]- (9CI) (CA INDEX NAME)



L72 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:923768 HCAPLUS
DN 136:53681
TI Preparation of cycloalkylalkanoic acids as **integrin** receptor antagonists
IN **Khanna, Ish Kumar**; Clare, Michael; Gasiecki, Alan F.; Rogers, Thomas; **Chen, Barbara**; **Russell, Mark**; **Lu, Hwang-Fun**
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D213-00
CC 27-16 (**Heterocyclic** Compounds (One **Hetero** Atom))
Section cross-reference(s): 1, 25, 63
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001096307	A2	20011220	WO 2001-US19104	20010615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002077321	A1	20020620	US 2001-882186	20010615

EP 1289960 A2 20030312 EP 2001-948363 20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2000-211781P P 20000615
WO 2001-US19104 W 20010615
OS MARPAT 136:53681
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The prepn. of compds. [I; A = heteroaryl (e.g., pyridine, imidazole, **thiazole**, oxazole, benzimidazole, imidazopyridine, etc.); n = 0-2, etc.; R1 = H, alkyl, etc.; R2, R3, R4, R5 = alkyl, alkoxy, etc.], their pharmaceutically acceptable salts and compns., and methods of selectively inhibiting or antagonizing the .alpha..nu..beta.3 and/or .alpha..nu..beta.5 **integrin**, are described. Thus, a multi-step synthesis of the trifluoroacetate salt of 2-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid (II) is given. Administration of I inhibits angiogenesis, tumor metastasis, tumor growth, osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, retinopathy, macular degeneration, arthritis, periodontal disease, smooth muscle cell migration, including restenosis and atherosclerosis, and viral diseases.

ST cycloalkylalkanoic acid prepn **integrin** antagonist inhibitor; antitumor agent cycloalkylalkanoic acid prepn; humoral hypercalcemia malignancy cycloalkylalkanoic acid prepn; antiarthritic cycloalkylalkanoic acid prepn; smooth muscle cell migration cycloalkylalkanoic acid prepn; angiogenesis cycloalkylalkanoic acid prepn; osteoporosis cycloalkylalkanoic acid prepn

IT Neoplasm
(humoral hypercalcemia of malignancy, treatment of; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT Eye, disease
(macula, degeneration, treatment of; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT Angiogenesis inhibitors
Antiarthritics
Antitumor agents
(prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT Eye, disease
(retinopathy, treatment of; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT Muscle
(smooth, cell migration, treatment of; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT Osteoporosis
(therapeutic agents; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.3; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT **Integrins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.5; prepn. of cycloalkyl alkanoic acids as **integrin** receptor antagonists)

IT 381225-73-6P 381225-74-7P 381225-75-8P 381225-76-9P 381225-77-0P
381225-79-2P 381225-80-5P 381225-81-6P 381225-82-7P 381225-83-8P
381225-84-9P, [2-[2-Methoxy-4-[3-(pyridin-2-ylamino)propoxy]phenyl]cyclopr

opyl]acetic acid 381225-85-0P 381225-86-1P 381225-87-2P
381225-88-3P 381225-89-4P 381225-90-7P, [2-[2-Fluoro-4-[3-(pyridin-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381225-91-8P
381225-93-0P 381225-94-1P 381225-95-2P 381225-96-3P,
3-[4-[3-(2-Pyridinylamino)propoxy]phenyl]cyclobutaneacetic acid
381225-97-4P 381225-98-5P 381225-99-6P 381226-00-2P 381226-01-3P,
[1-Methyl-2-[4-[2-[6-(2,2,2-trifluoroethylamino)pyridin-2-
yl]ethoxy]phenyl]cyclopropyl]acetic acid 381226-02-4P,
[2-[4-[2-(6-Ethylaminopyridin-2-yl)ethoxy]phenyl]cyclopropyl]acetic acid
381226-03-5P, [2-[4-[2-[6-(2-Methoxyethylamino)pyridin-2-
yl]ethoxy]phenyl]cyclopropyl]acetic acid 381226-04-6P,
[2-[4-[2-[6-(2,2,2-Trifluoroethylamino)pyridin-2-
yl]ethoxy]phenyl]cyclopropyl]acetic acid 381226-05-7P,
[2-[4-[2-[6-(3-Methoxypropylamino)pyridin-2-yl]ethoxy]phenyl]cyclopropyl]a
cetic acid 381226-06-8P, [2-[2-Acetoxy-4-[3-(pyridin-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-07-9P,
[1-Methoxymethyl-2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]cyclopropyl]ace
tic acid 381226-08-0P, [1-[(Methylsulfonyl)methyl]-2-[4-[3-(pyridin-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-09-1P,
[1-Pyridin-3-yl-2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]cyclopropyl]acet
ic acid 381226-10-4P, [1-Benzo[1,3]dioxol-5-yl-2-[4-[3-(pyridin-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-11-5P,
[1-(2,3-Dihydrobenzofuran-6-yl)-2-[4-[3-(pyridin-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-12-6P, [1-[
Isoxazol-3-yl]-2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]cycloprop
yl]acetic acid 381226-13-7P, [1-[**Isoxazol**-5-yl]-2-[4-[3-
(pyridin-2-ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-14-8P,
[1-[Oxazol-5-yl]-2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]cyclopropyl]ace
tic acid 381226-15-9P, [2-[4-[3-(Pyridin-2-ylamino)propoxy]phenyl]-1-[
thiazol-5-yl]cyclopropyl]acetic acid 381226-16-0P 381226-17-1P
381226-18-2P 381226-19-3P 381226-20-6P **381226-21-7P**
381226-22-8P 381226-24-0P **381226-25-1P** 381226-27-3P,
[2-[4-[3-(1H-Imidazol-2-ylamino)propoxy]phenyl]cyclopropyl]acetic acid
381226-28-4P, [2-[3-Fluoro-4-[3-(1H-imidazol-2-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-29-5P,
[2-[3-Fluoro-4-[3-(3H-imidazol-4-ylamino)propoxy]phenyl]cyclopropyl]acetic
acid 381226-30-8P, [2-[4-[3-(3H-Imidazol-4-ylamino)propoxy]phenyl]cyclop
ropyl]acetic acid 381226-31-9P, [2-[4-[3-(1H-Pyrazol-3-
ylamino)propoxy]phenyl]cyclopropyl]acetic acid 381226-32-0P,
[2-[3-Fluoro-4-[3-(1H-pyrazol-3-ylamino)propoxy]phenyl]cyclopropyl]acetic
acid 381226-33-1P, [1-Methyl-2-[4-[2-(6-methylaminopyridin-2-
yl)ethoxy]phenyl]cyclopropyl]acetic acid 381226-34-2P,
[2-[4-[2-(6-Ethylaminopyridin-2-yl)ethoxy]phenyl]-1-
methylcyclopropyl]acetic acid 381226-35-3P, [2-[4-[2-[6-(2-
Methoxyethylamino)pyridin-2-yl]ethoxy]phenyl]-1-methylcyclopropyl]acetic
acid 381226-36-4P, [2-[4-[2-[6-(3-Methoxypropylamino)pyridin-2-
yl]ethoxy]phenyl]-1-methylcyclopropyl]acetic acid 381226-37-5P,
[2-[4-[2-(6-Acetylaminopyridin-2-yl)ethoxy]phenyl]-1-
methylcyclopropyl]acetic acid 381226-38-6P, [2-[4-[2-(6-
Acetylaminopyridin-2-yl)ethoxy]phenyl]cyclopropyl]acetic acid
381226-90-0P 381226-91-1P 381226-92-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(prepn. of cycloalkyl alkanoic acids as **integrin** receptor
antagonists)

IT 74-95-3, Dibromomethane 75-11-6, Diiodomethane 79-04-9, Chloroacetyl
chloride 85-41-6, 1H-Isoindole-1,3(2H)-dione 105-58-8, Diethyl
carbonate 110-89-4, Piperidine, reactions 156-87-6, 3-Amino-1-propanol
351-54-2, 3-Fluoro-p-anisaldehyde 501-98-4, trans-4-Hydroxycinnamic acid
694-28-0 867-13-0 943-89-5, trans-4-Methoxycinnamic acid 1603-40-3
1895-39-2, Sodium chlorodifluoroacetate 2108-53-4, 3-(4-Methoxyphenyl)-2-
cyclopenten-1-one 2402-95-1, 2-Chloropyridine N-oxide 2446-83-5,



RN 381226-25-1 HCAPLUS
CN Cyclopropaneacetic acid, 2-[4-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]-1-(5-thiazolyl)- (9CI) (CA INDEX NAME)



=> d all hitstr l73

L73 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:594939 HCAPLUS
DN 131:214194
TI Preparation of pyridinylethoxyphenylbutanoates and related compounds as vitronectin receptor antagonists.
IN Miller, William H.; Gleason, John G.; Heerding, Dirk; Samanen, James M.; Uzinskas, Irene N.; Manley, Peter J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-44
ICS A61K031-505; C07D213-75; C07D239-42; C07D401-12; C07D409-12; C07D413-12
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 28
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945927	A1	19990916	WO 1999-US5232	19990310
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9901884	A	19990910	ZA 1999-1884	19990309
	CA 2323208	AA	19990916	CA 1999-2323208	19990310
	AU 9929033	A1	19990927	AU 1999-29033	19990310
	EP 1061921	A1	20001227	EP 1999-909952	19990310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				